MOgene Expands Digital Droplet PCR™ (ddPCR) Services
Summary
ST. LOUIS--(BUSINESS WIRE)--MOgene, a leading provider of genomics and molecular services worldwide, announced today an expansion of its Digital Droplet technology to include more automation capabilities. ddPCR is a disruptive, next-generation method of PCR testing that enables precise quantification of nucleic acids and targeted sequences. “ddPCR is a great solution for the increasing demand of consistent and reproducible data for testing of gene therapeutic products (e.g. CAR-T), viral vector titrations or any plant, animal and environmental studies,” said Kazima Saira, lab director for MOgene. “Absolute quantification of DNA/RNA that comes along with sample independence, great precision, sensitivity and much reduced inter- and intra-assay variability is the logical choice for measured and confident decisions in the clinical world.” MOgene provides a full range of genomics and molecular services for academic and commercial institutions, including support for discovery under research or regulated (CLIA and GxP) environments. MOgene, a pioneer in global genomic services since 2004, provides integrated, sample-to-insight solutions for a range of customers in the pharma, biotech, clinical and industrial markets.